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The present double-blind, randomized, placebo-controlled clinical trial intended to test whether ingestion of a natural combination
medicine (Tr14 tablets) affects serummuscle damage and inflammatory immune response after downhill running. 96male subjects
received Tr14 tablets, which consist of 14 diluted biological and mineral components, or a placebo for 72 h after the exercise test,
respectively. Changes in postexercise levels of various serum muscle damage and immunological markers were investigated. The
area under the curve with respect to the increase (AUCi) of perceived pain score and creatine kinase (CK) were defined as primary
outcome measures. While for CK the 𝑝 value of the difference between the two groups is borderline, the pain score and muscle
strength were not statistically significant. However, a trend towards lower levels of muscle damage (CK, 𝑝 = 0.05; LDH, 𝑝 = 0.06) in
the Tr14 group was shown. Less pronounced lymphopenia (𝑝 = 0.02), a trend towards a lower expression of CD69 count (𝑝 = 0.07),
and antigen-stimulated ICAM-1 (𝑝 = 0.01) were found in the verum group. The Tr14 group showed a tendentially lower increase
of neutrophils (𝑝 = 0.10), BDNF (𝑝 = 0.03), stem cell factor (𝑝 = 0.09), and GM-CSF (𝑝 = 0.09) to higher levels. The results of
the current study indicate that Tr14 seems to limit exercise-induced muscle damage most likely via attenuation of both innate and
adaptive immune responses. This study was registered with ClinicalTrials.gov (NCT01912469).
1. Introduction
An acute bout of physical exercise depending on duration
and intensity is known to induce changes of the immune
response of both the innate and the adaptive immune system.
Thereby, the numbers and functions of circulating leukocytes
are affected. Changes of leukocytes are regularly accompanied
by an exercise-induced increase of inflammatory cytokines
such as IL-6, IL-10, and IL-1ra [1]. Eccentric exercise like
downhill running is a special exercise mode which is known
to cause substantialmuscle damage followed by a pronounced
inflammatory response. This muscle damage is accompanied
by muscle soreness, which regularly occurs 12–48 hours after
the eccentric exercise bout and which was termed delayed
onset of muscle soreness (DOMS). DOMS is furthermore
accompanied by stiffness or tenderness on palpation and a
loss of muscle force [2, 3].
Actually, there are two different mechanisms that explain
the induction of DOMS. Firstly, mechanical stress generated
during the eccentric exercise is considered as onemechanism
[4].Thereby, the increased tension per individual cross bridge
and the stretching forces on sarcomeres induce microtrauma
in muscle fibers [3]. Microscopically, observations show rup-
tures of Z-discs and A-bands and the subsequent dissolution
of sarcomere structures in individual muscle fibers [5, 6].
Structural damage is accompanied by increased cytosolic
calcium concentrations, which activate proteolytic enzymes
and increase cell membrane permeability [3]. The result is
release of muscle enzymes such as creatine kinase (CK) into
the interstitial fluid [7]. Secondly, it is suggested thatDOMS is
based on inflammatory responses after eccentric exercise [4].
Thereby, several studies described the occurrence of a local
inflammation in muscle tissue. Within this inflammation,
migration of neutrophils and macrophages into the damaged
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tissue several hours after exercise is observed. Neutrophils
eliminate cell fragments and perform reorganization pro-
cesses via reactive oxygen species. Both neutrophils and
macrophages are involved in the release of cytokines such as
IL-1, TNF-𝛼, and IL-6 [3, 8].
Several approaches were done to prevent muscle soreness
and stimulate regeneration. Some studies investigated the
effect of nonsteroidal anti-inflammatory drugs (NSAIDs)
or antioxidants [9–11]. Others examined the application of
various physical therapy methods [12, 13]. Regarding the use
of antioxidants (e.g., vitamin C and vitamin E), no clear effect
on reduction of muscle damage was found [11]. Similarly,
neither cryotherapy nor stretching exercise was effective in
treating exercise-inducedmuscle damage [12, 13]. In contrast,
studies about the administration of NSAIDs have shown
contradictory results.While some studies showed no changes
after treatment with NSAIDs [9, 10], others demonstrated
lower symptoms of DOMS [14, 15]. However, athletes have
to consider several side effects of the regular use of NSAIDs
such as upper gastrointestinal bleeding and perforation, renal
injury, liver injury, and heart failure [16].
Therefore, the current study intended to test the effect
of the well tolerated natural combination medicine Tr14
on DOMS. Tr14 consists of 14 diluted biological and
mineral components. It is composed mainly of plants of the
Compositae family (chamomile, common daisy, common
marigold, common yarrow, mountain arnica, narrow-leaved
purple coneflower, and purple coneflower). They showed in
various studies immunomodulating effects. For example, for
both chamomile and coneflower, anti-inflammatory effects
have been shown [17, 18]. The residual plant components
of Tr14 are composed of different plant families (comfrey,
common witch-hazel, deadly nightshade, St. John’s wort, and
wolf ’s bane). For St. John’s wort, anti-inflammatory effects
have been shown in an in vivo study [18]. Tr14 also consists
of two mineral components (calcium sulfide and Mercurio-
amidonitrate). Evidence for immunomodulatory effects of
Tr14 comes from humans [19–21], animals [22, 23], and in
vitro [21, 24] studies. Clinical evidence for Tr14 and composi-
tion in more detail was reviewed by Schneider [25]. Gonza´lez
de Vega et al. demonstrated in a human clinical trial that Tr14
decreased pain and improved joint function in acute ankle
sprain when topically applied [19]. Recently, we observed in a
human clinical trial that Tr14 has effects on various immune
parameters of the exercise-induced immune response [20].
Here, we showed that Tr14 reduced the inflammatory
response of the innate immune system while the response of
proinflammatory cytokines was promoted. The animal study
of Oberbaum et al. demonstrated that Tr14 increased IL-1𝛽 in
an in vivo sepsis model in rats [23]. Furthermore, Lussignoli
et al. showed that Tr14 significantly reduced IL-6 production
in rats with edema [22]. In contrast, Porozov et al. showed in
an “in vitro” study that Tr14 inhibits the secretion of proin-
flammatory cytokines such as IL-1𝛽, CXCL8, and TNF-𝛼
in resting as well as activated immune cells [24].
The present double-blind, randomized, placebo-
controlled study follows up our research on effects of Tr14
in strenuous exercise paradigm, this time examining
exercise-induced muscle soreness. We hypothesized that
Analyzed: n = 47Analyzed: n = 48
Dropout: n = 1Dropout: n = 0
Lost to follow-up: n = 0Lost to follow-up: n = 0
Randomized: n = 96
Did not receive placebo: n = 1
Received placebo: n = 47
Allocated to placebo: n = 48
Did not receive Traumeel: n = 0
Allocated to Traumeel: n = 48
Received Traumeel: n = 48
Excluded: n = 14
Assessed for eligibility: n = 110
Figure 1: Study flow chart. 110 subjects were assessed for eligibility
in the clinical trial and thereof 96 subjects were randomized. There
was one dropout in the placebo group.
Tr14 is effective in limiting exercise-induced muscle damage
and inflammatory response. The results might be helpful
in optimizing load-recovery cycles during various training
regimes thereby improving the training effectivity.
2. Methods
2.1. Study Design. The present study was conducted as a
double-blind, randomized, placebo-controlled clinical trial.
This monocenter study was performed at the Department
of Sports Medicine, University of Giessen. The study pro-
tocol was approved by the local ethics committee and the
Federal Institute for Drugs and Medical Devices (EudraCT
2009-010898-21). The study was registered with Clinical-
Trials.gov (NCT01912469). The study flow chart according
to CONSORT is shown in Figure 1. Initially, 110 subjects
were examined for their medically approved unrestricted
participation in sport using an incremental protocol on a
treadmill. After the test, 14 subjects were not included into
the study because they did not meet the inclusion criteria
of the study (see below). Hence, a total of 96 subjects were
enrolled in the study and randomized either to Tr14 (𝑛 = 48)
or to placebo (𝑛 = 48). A total of 95 subjects were analyzed
because of one dropout due to a study related adverse event
in the placebo group before intake of study medication. The
duration of subject study participation was four days. The
screening was performed within 8 days prior to study entry.
On day one, the subjects came fasting to the study center
and got a standardized breakfast and the following proce-
dure was performed: inclusion/exclusion criteria rechecking,
subject randomization, acute bout of eccentric exercise, data
collection at three different time points, and dispensing of
study medication (Figure 2). Before, immediately after, and
three hours after exercise, various analyses were performed
(blood samples, strength measurement, and SF-McGill Pain
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Table 1: Subject characteristics of placebo and Tr14 group (the median with the 1st and 3rd quartile is shown in parentheses).
Placebo (𝑛 = 47) Tr14 (𝑛 = 48) 𝑝 value
Age (years) 25.0 (23.0; 28.0) 24.0 (21.0; 27.0) 0.20
Height (cm) 183.0 (176.0; 187.0) 182.0 (176.5; 186.5) 0.75
Weight (kg) 79.4 (72.5; 84.0) 76.8 (67.9; 86.3) 0.73
BMI (kg/m2) 23.8 (21.9; 25.4) 23.7 (21.6; 25.7) 0.64
VO
2max (mL/min/kg) 43.9 (39.7; 47.3) 45.7 (42.8; 48.9) 0.20
HR at 80% VO
2max (beats/min) 161.0 (152.0; 170.0) 164.5 (153.5; 174.0) 0.29
BMI: body mass index; HR: heart rate; VO2max: maximum oxygen uptake.
Median with the 1st and 3rd quartile in parentheses.







Figure 2: Experimental design. The figure shows the different time
points of data collection. On day one, the data collection was
performed immediately before, immediately after, and three hours
after exercise (45min downhill running). Follow-up visits were
performed 24 h, 48 h, and 72 h after exercise.The intake of the study
medication started directly after exercise.
Questionnaire). The subjects were not allowed to consume
any food until three hours after exercise. In contrast, water
was allowed ad libitum. Follow-up visits were performed at
24 h, 48 h, and 72 h after exercise.The subjects were requested
48 h prior to study participation and during the study to
refrain from strenuous physical activity.
2.2. Subjects. The subject characteristics showed only
marginal differences between the two groups (Table 1).
Subjects were included if they met all inclusion criteria and
none of the exclusion criteria. Subjects were eligible for the
study if they were male, were aged ≥ 18 and ≤ 40 years,
had BMI ≥ 18.5 and < 27.5 kg/m2, had maximum relative
oxygen uptake (VO
2max) < 53mL/kg⋅min, were healthy,
were nonsmokers, had medically approved unrestricted
sports participation as shown by diagnostic performance
test conducted on treadmill for no longer than three months
prior to study entry, and were willing to provide informed
consent. If any of the following exclusion criteria existed,
the subjects were not included in the study: regular eccentric
exercise training, weekly training volume ≥ 6 hours, use of
dietary supplements, chronic immune deficiency, current
infection, heart and/or circulation disorders, musculoskeletal
disorders, nothing that requires a systemic therapy, hyper-
sensitivity to botanicals of the Compositae family, lactose
intolerance, illicit drug or alcohol abuse, and participation in
another clinical trial within four weeks prior to study entry.
2.3. Exercise Protocol. The subjects were instructed to run
downhill (10% incline) on a treadmill (h/p/cosmos quasar
med 4.0, h/p/cosmos Sports & Medical GmbH, Nussdorf,
Traunstein, Germany) as a means to eccentric exercise at
a heart rate (HR) corresponding to 80% of VO
2max. The
duration of the eccentric exercise was set to 45min unless
the subjects were forced to quit earlier due to exhaustion.
The protocol began with a short warm-up. Afterwards,
the treadmill speed increased to 8 km/h and the downhill
running started. The heart rate was regulated manually by
speed adjustment on the running belt.
2.4. Study Medication. Tr14 tablets are a registered natural
combination medication. The study medication was man-
ufactured by Biologische Heilmittel Heel GmbH, Baden-
Baden, according to the German Homeopathic Pharma-
copoeia (HAB), current EU-GMP guidelines, and pertinent
national regulations. Participants and investigators were
blinded to the study medication by identical color, smell,
taste, and size. The 1-to-1 randomization with a block size of
eight was conducted by DATAMAP GmbH, Freiburg, Ger-
many, according to the company internal SOP. The subjects
were randomized on day one directly before the first study
related procedure was carried out. Time of randomization
and study entry were defined by taking the first blood sample.
Tr14 consists of the following active components (D stands
for dilutions in increments, amounts per 300mg): Achillea
millefolium (D3, 15mg), Aconitum napellus (D3, 30mg),
Arnica montana (D2, 15mg), Atropa belladonna (D4, 75mg),
Bellis perennis (D2, 6mg), Calendula officinalis (D2, 15mg),
Chamomilla recutita (D3, 24mg), Echinacea angustifolia (D2,
6mg), Echinacea purpurea (D2, 6mg),Hamamelis virginiana
(D2, 15mg), Hepar sulfuris (D8, 30mg), Hypericum perfora-
tum (D2, 3mg),Mercurius solubilis Hahnemanni (D8, 30mg),
and Symphytum officinale (D8, 24mg); and it also consists
of the following inactive components: lactose (6mg) and
magnesium stearate (1.5mg). All components are prepared
according to Homeopathic Pharmacopoeia. The placebo
tablet consists of 300mg lactose monohydrate and 1.5mg
magnesium stearate.
The subjects received one tablet every 15 minutes until
eight tablets were taken (dissolved in the mouth) after the
exercise test. In addition, the subjects ingested two tablets 6 h
and 10 h after the exercise test.On the following twodays, they
received two tablets three times a day and on the fourth day
they took two tablets in themorning.The total study dose was
26 tablets.
4 Mediators of Inflammation
2.5. Blood Collection. At each data collection point, approx-
imately 19mL of blood was taken from the antecubital
vein using Safety-MultiflyNeedle (Sarstedt, Nu¨mbrecht, Ger-
many).
2.6. White Blood Cell Count and Lymphocyte Activation
and Apoptosis. The tube with EDTA blood (2.7mL EDTA
K tubes, Sarstedt, Nu¨mbrecht, Germany) was analyzed for
white blood cell count using the optoelectronic principle
(XE2100, Sysmex, Norderstedt, Germany). For the deter-
mination of apoptosis and surface markers, the peripheral
blood mononuclear cells (PBMCs) were isolated by using
lithium-heparinized blood and density gradient centrifu-
gation. Subsequently, the cells were labeled with FITC-
conjugated (Annexin V, anti-human CD62L, anti-human
CD69, and anti-human CD95R; ImmunoTools, Friesoythe,
Germany) and PE-conjugated (anti-human CD95L; BioLe-
gend, San Diego, USA) antibodies. Next, the lymphocytes
were gated by flow cytometry and measured (Coulter Epics
XL-MCL, Beckman-Coulter, Brea, USA). For more details,
see works of our own group [26].
2.7. Soluble Inflammatory Mediators. The following param-
eters were measured using multiplex ELISA (Myriad RBM,
Austin, Texas) in stimulated whole-blood cultures: BDNF,
CCL2, CCL3, CCL4, CXCL8, CCL11, Factor VII, GM-CSF,
ICAM-1, IFN-𝛾, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-10, IL-
12p40, IL-12p70, IL-15, IL-17, IL-18, IL-23, IL-1ra, IL-1𝛼, IL-
1𝛽, MMP-3, MMP-9, SCF, TNF-𝛼, TNF-𝛽, and VEGF. Here,
1mL of whole blood was withdrawn in blood collection
tubes (TruCulture, EDI GmbH, Reutlingen, Germany) by
Safety-Multifly Needle (Sarstedt, Nu¨mbrecht, Germany).The
collection tubes contained the stimulants lipopolysaccharide
(LPS) from Escherichia coli serotype O55:B5 and Staphylo-
coccus enterotoxin B (SE-B) in a concentration of 0.1 𝜇g/mL.
Each tube was incubated for 24 h in a dry block incubator
(VLMGmbH, Bielefeld, Germany) at 37∘C. After 24 h, a valve
separator was inserted into the tube and the samples were
stored at −80∘C until further analyses. For more details, see
work of our own group [20]. Additionally, six inflammatory
mediators were measured in serum samples using multiplex
ELISA: CCL2, CXCL8, IL-1ra, IL1- 𝛽, IL-6, and TNF-𝛼.
2.8. Muscle Damage and Recovery Markers. The maximum
isometric strength of the anterior (extension) and pos-
terior (flexion) thigh muscles was used as a marker of
exercise-induced muscle damage and recovery. The Schnell
m3-Diagnos multifunctional training and analysis station
(Schnell GmbH, Peutenhausen, Germany) was utilized for
the measuring of the muscle strength. Furthermore, creatine
kinase (CK) and lactate dehydrogenase (LDH) in serum
(1.2mL serum Z tubes, Sarstedt, Nu¨mbrecht, Germany) were
additionally used as markers for exercise-induced muscle
damage. The Short Form McGill Pain Questionnaire (SF-
MPQ) was used to evaluate the experience of pain from the
subjects. The SF-MPQ contains ten questions about relating
to the sensory level of pain experience and four questions
about relating to the affective status. In addition, the SF-MPQ
contains a 5-value Likert scale for the overall pain experience
and a visual analogue scale (VAS) for the momentary pain
intensity [27].The total score aswell as theVASwas evaluated.
2.9. Statistical Analysis. Statistical analyses were conducted
on the intention-to-treat (ITT) principle andwere performed
using SAS V 9.3 (SAS Institute, Cary, NC). All randomized
and treated subjectswere analyzed according to the intention-
to-treat principle. The “area under the curve with respect to
increase” (AUCi) was calculated with reference to time point
before exercise. Perceived pain score and CK were defined as
the primary outcome measure. AUCi was calculated using
the trapezoidal rule [28]. In order to identify a potential
difference between the two groups, a median test of AUCi
was performed. All other outcome measures were included
as secondary outcome measures.
A𝑝 value of≤0.05 was accepted as statistically significant.
The 𝑝 values of all secondary outcome measures were set to
≤0.05. The 𝑝 values were two-tailed. There was no multiple
test adjustment of 𝛼-error.
3. Results
3.1. Compliance to Exercise Protocol. Compliance with exer-
cise protocol was assessed using the following variables:
completion of exercise protocol over 45min (Tr14: 𝑛 = 48,
100%; placebo: 𝑛 = 44, 93.6%), time to exhaustion if the
subject did not accomplish the exercise test (Tr14: 45 ± 0min;
placebo: 40.3 ± 4.6min), and average HR throughout the
exercise protocol (Tr14: 164 ± 12.9 BPM; placebo: 161.8 ±
10.4 BPM).
3.2. Muscle Damage Markers and Recovery. The maximum
isometric strength (flexion and extension) decreased after
exercise in both groups (Supplemental Table 1 in Supplemen-
taryMaterial available online at http://dx.doi.org/10.1155/2016/
1693918). The muscle strength (flexion) showed a minimum
immediately after exercise in the Tr14 group and 24 h after
exercise in the placebo group. Both groups demonstrated a
slight increase 48 h after exercise. In contrast, the muscle
strength (extension) indicated a minimum immediately after
exercise in the Tr14 group and 3 h after exercise in the placebo
group and a slight increase 24 h after exercise in both groups.
Additionally, an exercise-induced increase of CK, LDH, and
pain score was observed in both groups (Supplemental Table
1). A maximum increase of LDH was demonstrated three
hours after exercise in both groups. In contrast, CK and the
pain score peaked at 24 h after exercise in both groups. CK
levels, which were one of the primary outcome measures,
showed borderline statistical significance (𝑝 = 0.05) and
LDH (𝑝 = 0.06) with lower values in the Tr14 group
(Table 2). Additionally, the subjects were classified into three
groups according to their peak CK values: low responders
(<500U/L), medium responders (500–2000U/L), and high
responders (>2000U/L) (Supplemental Table 2). However,
we could not show any differences between placebo and Tr14.
Similarly, no group differences were found for either total or
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Table 2: AUCi median values from all outcome parameters and the
𝑝 value of median test.
AUCi median values 𝑝 value
Placebo Tr14
Muscle damage and recovery
CK 1.7 × 106 1.1 × 106 0.05
LDH 1.0 × 105 6.1 × 104 0.06
Strength (extension) −2.7 × 105 −2.2 × 105 0.87
Strength (flexion) −1.2 × 105 −8.7 × 104 0.30
Pain score, total 1.2 × 105 1.4 × 105 0.36
Pain score, VAS 9.3 × 104 1.1 × 105 0.36
White blood cell count
Basophils 0 0 0.85
Basophils absolute −5.4 −6.9 0.41
Eosinophils −1.2 × 103 −2.2 × 103 0.41
Eosinophils absolute −58.3 −66.0 0.41
Leukocytes 2.2 × 103 3.4 × 103 0.92
Lymphocytes −1.7 × 104 −7.9 × 103 0.02
Lymphocytes absolute −3.9 × 102 −1.2 × 102 0.21
Monocytes −4.1 × 102 −4.0 × 103 0.21
Monocytes absolute 1.4 × 102 63.2 0.41
Neutrophils 2.0 × 104 1.4 × 104 0.21
Neutrophils absolute 3.4 × 103 2.3 × 103 0.10
Lymphocyte activation and apoptosis
Annexin V −1.9 × 103 −3.7 × 103 0.67
Annexin V absolute −44.5 −66.2 0.92
CD62 4.1 × 103 −4.7 × 103 0.21
CD62L absolute −2.9 × 102 −1.6 × 102 0.60
CD69 1.1 × 102 2.8 × 102 0.41
CD69 absolute −0.4 5.4 0.07
CD95R 3.1 × 103 5.9 × 103 0.18
CD95R absolute −0.8 36.2 0.20
CD95L −5.5 × 102 5.1 × 103 0.47
CD95L absolute −7.0 40.5 0.34
Soluble inflammatory mediators
CXCL8 4.9 × 107 3.0 × 107 0.40
CXCL8 serum 1.2 × 103 1.9 × 103 0.60
CCL2 8.6 × 106 4.0 × 107 0.40
CCL2 serum 1.4 × 105 1.3 × 105 0.61
CCL3 5.0 × 107 3.8 × 107 0.40
CCL4 2.7 × 108 3.4 × 108 0.67
CCL11 −1.3 × 104 −6.3 × 104 0.20
Factor VII 2.5 × 104 −3.8 × 104 0.40
ICAM-1 1.3 × 104 −2.9 × 103 0.01
IFN-𝛾 2.6 × 106 2.3 × 106 0.67
IL-1𝛼 2.3 × 102 2.6 × 102 0.67
IL-1𝛽 1.4 × 107 9.0 × 106 0.40
IL-1𝛽 serum 3.8 × 102 3.2 × 10−7 0.46
IL-1ra 4.5 × 106 4.5 × 106 1.00
IL-1ra serum −4.8 × 104 1.8 × 104 0.34
IL-2 −2.4 × 105 −4.0 × 104 0.40
Table 2: Continued.
AUCi median values 𝑝 valuePlacebo Tr14
IL-4 −3.0 × 104 3.8 × 104 0.67
IL-5 1.0 × 103 4.6 × 103 0.20
IL-6 3.8 × 107 2.9 × 107 0.67
IL-6 serum 0 0 0.50
IL-7 4.0 × 104 3.5 × 103 0.67
IL-10 1.9 × 105 2.1 × 104 0.40
IL-12p40 2.3 × 103 5.0 × 103 0.67
IL-12p70 −8.6 × 104 1.7 × 104 0.03
IL-15 6.1 × 102 5.0 × 102 0.40
IL-17 −5.4 × 103 −3.9 × 103 1.00
IL-18 2.0 × 105 1.0 × 105 0.09
IL-23 2.8 × 103 5.9 × 103 0.67
TNF-𝛼 1.2 × 107 1.1 × 107 1.00
TNF-𝛼 serum 0 0 0.58
TNF-𝛽 5.9 × 103 6.0 × 103 1.00
Growth factors
BDNF 4.5 × 103 −1.9 × 102 0.03
GM-CSF 2.0 × 104 7.5 × 104 0.09
IL-3 9.4 0.8 0.40
SCF 5.7 × 105 2.4 × 105 0.09
VEGF 1.2 × 105 8.1 × 104 0.40
Matrix metalloproteinases
MMP-3 5.3 × 103 3.9 × 103 0.20
MMP-9 6.3 × 104 5.0 × 104 0.40
Acute phase protein
CRP 2.4 × 103 2.3 × 103 0.76
BDNF: brain-derived neurotrophic factor; CK: creatine kinase; CRP: C-
reactive protein; GM-CSF: granulocyte macrophage colony-stimulating
factor; ICAM-1: intercellular adhesionmolecule 1; IFN-𝛾: interferon-gamma;
LDH: lactate dehydrogenase; MMP: matrix metalloproteinase; SCF: stem
cell factor; TNF: tumor necrosis factor; VEGF: vascular endothelial growth
factor.
VAS pain score or for the strength measurements (extension
and flexion) (Table 2).
3.3. White Blood Count, Lymphocyte Activation, and Apopto-
sis. There was an exercise-induced increase of leucocytes in
both groups. Thereby, neutrophils and monocytes increased
three hours after exercise while lymphocytes increased one
hour after exercise and subsequently decreased in both
groups (Supplemental Table 1). The Tr14 group indicated less
pronounced postexercise lymphopenia (𝑝 = 0.02) (Table 2).
Also, the lymphocyte activation marker CD69 count showed
a trend towards a lower level in the Tr14 group (𝑝 = 0.07)
(Table 2). Also, a trend towards lower level neutrocytosis was
observed in the Tr14 group (𝑝 = 0.10) (Table 2). For all other
immune cell numbers and apoptosis and surface markers, no
treatment effects could be shown (Table 2).
3.4. Soluble Inflammatory Mediators. Various anti- (e.g., IL-
1ra and IL-10) and proinflammatory (e.g., IL-1𝛽, IL-6, and
TNF-𝛼) cytokines reached their maximum three hours after
exercise and subsequently decreased to baseline values within
72 hours in both groups (Supplemental Table 1). However,
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these mediators showed no statistically significant difference
between the two groups. In contrast, other inflammatory
mediators such as ICAM-1, IL-18, and IL-12p70 showed group
differences. The Tr14 group indicated a lower expression
of antigen-stimulated ICAM-1 (𝑝 = 0.01) (Table 2). Fur-
thermore, antigen-stimulated cytokine IL-18 showed a trend
towards a lower level in the Tr14 group (𝑝 = 0.09) (Table 2).
On the contrary, we found a lower decrease of antigen-
stimulated IL-12p70 in the verum group (𝑝 = 0.03) (Table 2).
For all other inflammatory mediators, no treatment effects
could be shown (Table 2).
3.5. Growth Factors. The antigen-stimulated growth factors
(BDNF, GM-CSF, IL-3, SCF, and VEGF) were enhanced by
exercise in both groups (Supplemental Table 1). In addition,
three of the growth factors showed group differences. There
was a lower expression of antigen-stimulated BDNF (𝑝 =
0.03) and a trend towards lower values of antigen-stimulated
SCF (𝑝 = 0.09) in the Tr14 group (Table 2). On the contrary,
antigen-stimulated GM-CSF demonstrated a trend towards
a higher expression in the Tr14 group (𝑝 = 0.09) (Table 2).
No treatment effects could be found for either IL-3 or VEGF
(Table 2).
4. Discussion
The result of the current study demonstrated that muscle
damage and inflammatory response were slightly modulated
by Tr14 after acute bout of eccentric exercise. It also corrob-
orates the previously published results in another strenuous
exercise setting [20]. While trends towards lower levels on
parameters of muscle damage were observed, Tr14 affected
lymphopenia, cellular and soluble activation markers, low-
ered exercise-induced neutrocytosis, and reduced the expres-
sion of selected growth factors such as BDNF.Therefore, Tr14
might limit the destructive processes after eccentric exercise.
Relevance for improved regeneration has not been shown in
the analyzed parameters.Whether these effects on the cellular
recovery in the postexercise period might have any relevance
for the adaptational training response remains to be shown.
The eccentric exercise protocol was effective in inducing
distinct muscle damage as indicated by a loss of muscle
strength and release of intracellular proteins such as CK
and LDH in both groups [3, 7]. However, there were no
group differences in muscle strength, which is one of the
most reliable markers of exercise-induced muscle damage
[29]. We assume that the lack of differences is due to
the large variability of muscle damage [30]. However, our
data indicated a trend towards lower levels of serum mus-
cle damage markers following ingestion of Tr14 after the
eccentric exercise suggesting a protective effect on muscle
integrity. It can be speculated that this effect could be even
more pronounced if Tr14 ingestion had started before and
not after the exercise bout. Previous studies focused on
individual components of Tr14 on the inflammatory response
after exercise [31, 32]. Tr14 consists mostly of components
of the Compositae family such as arnica. Application of
isolated arnica demonstrated no effects on muscle damage
[31, 32]. Lussignoli et al. examined the effect of Tr14 and its
components in rats with edema [22]. They found a more
rapid decrease of paw edema in rats treated with Tr14,
associated with an improved process of healing. Accordingly,
it is concluded that the effect of Tr14 seems not to depend on
an individual component, but the synergy of all components
of Tr14. This may explain that arnica alone did not affect any
parameter of muscle damage. Regarding the use of CK, it has
to be recognized that a single marker of muscle damage is
anyway a limitation of our and other studies because there is a
large interindividual variability of CK.Therefore, there is still
a discussion on whether CK is a reliable marker for muscle
damage [33]. In many studies, the subjects were divided into
low, medium, and high responders based on CK activity
[34, 35]. Paulsen et al. proposed to make this classification
for a better presentation and interpretation [36]. Although
the CK response showed high interindividual variations, we
cannot conclude any differences from the𝑝 value between the
groups (Supplemental Table 2).
In addition to muscle damage, the consecutive inflam-
matory process is considered to be a major cause of DOMS
[37]. It is known that the expression of various chemokines
in damaged muscle tissue is followed by mobilization of
leukocytes into the circulation and eventually their infiltra-
tion into muscle tissue. In line with previous studies, an
exercise-induced increase of circulating leukocyteswas found
followed by postexercise lymphopenia [37]. It is proposed
that lymphocytes initially increase due to redistribution
processes from lymphatic and nonlymphatic organs followed
by apoptotic cell death and/or redistribution into tissues
[38, 39]. In this regard, adhesion molecules such as selectins
and ICAM-1 play an important role in transmigration of
lymphocytes to the inflammation site [40]. Ingestion of Tr14
induced a lower decrease of lymphocytes, a reduced expres-
sion of antigen-stimulated ICAM-1, and a trend towards
a lower expression of absolute CD69 in the Tr14 group.
Since CD69 is known to stimulate cell proliferation and
cytokine secretion, all of these effects of Tr14 are suggested to
represent less pronounced activation of the adaptive immune
system [41]. Thereby, the lower levels of cell activation and
adhesion molecule expression might be responsible for lower
emigration of lymphocytes into muscle thereby contributing
to the lower lymphopenia. Indirectly, this might also reflect a
lower level of damaged muscle tissue.
Besides components of the adaptive immune system, also
the innate immune system plays an important role in muscle
damage [42]. In accordance with previous studies, eccentric
exercise was accompanied by substantial neutrophilia [37].
Here, we showed that the exercise-induced increase of neu-
trophils was lower by trend after ingestion of Tr14. In general,
it is assumed that neutrophils are the first cells which infiltrate
the damaged tissue [42]. These cells eliminate cell fragments
and performed reorganization processes via reactive oxygen
species [43]. The lower peripheral increase of neutrophils in
the Tr14 group is the result of lower mobilization into the
blood which might be the result of a lower expression of
hematopoietic factors [37]. In line with this data, Pilat et
al. showed a lower level of neutrophils in the Tr14 group
after a concentric exercise test [20]. Possibly, Tr14 affects
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the number of mobilized neutrophils by inhibition of GM-
CSF, which leads to reduced recruitment of neutrophils into
circulation. However, such an underlying mechanism could
not be confirmed in the current study.
In response to exercise, cells of the innate immune
system are also known to produce several proinflammatory
cytokines [37]. In this regard, we showed that the proin-
flammatory antigen-stimulated cytokine IL-12p70 showed a
higher level after exercise in the Tr14 group. IL-12 is produced
mainly from dendritic cells, monocytes, and macrophages.
It plays an important role in the regulation of T helper
1 cell (Th1) responses [44]. A higher level of IL-12p70
indicates a higher type 1 T cell response after exercise.
It was demonstrated in a stimulated human whole-blood
model that the production of IL-12p70 is inhibited by var-
ious stress hormones (dexamethasone, norepinephrine, and
epinephrine) [45]. Possibly, Tr14 caused a reduced stress
response and lower production of stress hormones resulting
in an extenuated T cell mediated immune response. However,
no stress hormones were analyzed in this study to support
this assumption. Oberbaum et al. demonstrated in an in vivo
sepsis model in rats a higher expression of proinflammatory
cytokine IL-1𝛽 in the Tr14 group [23]. Similarly, Pilat et al.
demonstrated a higher expression of the proinflammatory
cytokines IL-1𝛽 and IL-1𝛼 after a concentric exercise test in
the Tr14 group [20]. It is suggested that the higher levels
of proinflammatory cytokines have a protective effect [23]
because a previous injection of IL-1𝛽 showed improved
survival in a murine sepsis model [46]. In contrast, in a
study of Porozov et al., a lower expression of proinflammatory
cytokines IL-1𝛽, TNF-𝛼, and CXCL8 in the Tr14 group was
found [24]. This study examined the effects of Tr14 in an in
vitro model, so the methodological component might have
an impact on the results. However, we suggest that the contra-
dictory findings on Tr14might also be caused by a pleiotropic
effect induced by variable effects on different target cells [47].
Altered expression of proinflammatory cytokines might
also be due to redox disturbances which are known to
affect MAPK and NF-𝜅B signaling [48, 49]. In this regard,
Michailidis et al. indicated that N-acetylcysteine lowered
proinflammatory response after eccentric exercise [49]. They
suggested that the attenuation of NF-𝜅B/MAPK by antiox-
idants might lower proinflammatory response. However, in
the current study, no markers of oxidative stress or related
signaling pathways have been analyzed.
It is widely accepted that the exercise-induced muscle
damage is part of a muscular adaptation process. This adap-
tation is visible in the so-called “repeated bout effect,” a term
which describes lower level of muscle damage and DOMS
after a repeated eccentric exercise bout [50]. In this regard,
it is assumed that in response to muscle damage growth
factors are expressed which play a role in the regeneration
and adaptation of skeletal muscle. In this regard, Menetrey
et al. showed that basic fibroblast growth factor (b-FGF),
insulin growth factor type 1 (IGF-1), and at a less intensity
nerve growth factor (NGF) amplify muscle regeneration in
vivo [51]. In general, growth factors play a role in exercise-
induced stimulation of cellular growth, proliferation, and
differentiation [52]. In our study, we analyzed various growth
factors like BDNF, SCF, GM-CSF, IL-3, and VEGF. BDNF
belongs to the neuropathic family as well as NGF [53]. In the
Tr14 group, a lower expression of BDNF and a trend towards
lower expression of SCF were found. There is some evidence
that BDNF plays a role during myogenic differentiation if it
is expressed by satellite cells [54]. Similarly, SCF is suggested
to be involved in the stimulation of muscle-derived stem
cell [55] and plays a major role in hematopoiesis [56]. The
reduced expression of BDNFand SCF in theTr14 groupmight
indicate a reduced need for tissue regeneration. However,
if the reduction of muscle damage is the reason for lower
growth factors, expression remains to be shown.
For the interpretation of the current results, it has to be
considered that a stimulated in vitro whole-blood culture was
used for analysis of the cytokines and growth factors. An
advantage of using whole-blood culture is that the cellular
environment is similar to in vivo blood conditions [57].
However, the included stimulants LPS and SEB stimulate
primarily monocytes and lymphocytes, respectively [58, 59].
This means that the effects are primarily dependent on
these cell types. The complete synergy of the cytokines in
all compartments is not shown in this model, so that no
conclusions can be concluded about the exact mechanism of
the effect of Tr14.
In our study, Tr14 was ingested after the exercise bout.
Possibly, the ingestion of Tr14 before the eccentric exercise
may have a more pronounced preventive effect. Accordingly,
further studies including the analysis of detailedmechanisms
of the effects of Tr14 still need to be performed. Besides
this, a potential negative effect of anti-inflammatory drugs on
adaptation processes has to be considered and investigated in
future studies.
In summary, these results indicate that Tr14 affects ex-
ercise-induced muscle damage leading to reduced activation
of the innate and the adaptive immune system in response to
eccentric exercise. Possibly, these anti-inflammatory actions
accelerate the regeneration processes. However, any practical
impact for athletes remains to be shown.
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